Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2019 / Aug / Time to Transform the Glaucoma Treatment Paradigm
Glaucoma Research & Innovations Health Economics and Policy Sponsored

Time to Transform the Glaucoma Treatment Paradigm

8/10/2019 1 min read

Share

In April this year, we published the results of our six-year NIHR-funded trial assessing primary treatment for newly-diagnosed glaucoma (1). We compared two interventions; selective laser trabeculoplasty – a well-known, but less widely adopted first-line treatment – and the current standard of care, eye drops. Seven hundred and eighteen patients were randomly allocated to a group and monitored to establish which intervention was more effective in lowering intraocular pressure (IOP). We managed to retain over 90 percent of those patients, which is not only a feat in itself, but a major metric of a successful study. The results were surprising – even to us.

SLT was found to be as effective, if not more effective, than eye drops at controlling IOP - giving drop-free control to three quarters of the patients in the laser group for at least 36 months. They also required fewer surgeries – there were no trabeculectomies needed in the SLT group, compared with 11 in the medication-first group – and fewer cataract extractions, a common side effect of habitual drop use. SLT was also significantly more cost effective than eye drops. We worked out that using SLT as a first-line treatment resulted in savings of £451 per patient in specialist ophthalmology costs. To put that in perspective, SLT could save the NHS £1.5 million a year in treatment for newly-diagnosed patients, with the potential to save a further £250 million a year if SLT proves to be as effective in previously-diagnosed patients.

Our final test came down to quality of life outcomes, which was assessed using the EQ-5D questionnaire – a generic tool eliciting utility values in multiple settings. Promisingly, we found no clinically-significant difference between the two groups. This, paired with our findings on disease progression, achievement of target intraocular pressure and cost, suggest that we should shift our treatment paradigm to primary SLT – something that seems to be happening around the world already. I’ve had conversations with senior colleagues in Australia, America and Europe who are all now using SLT as a first-line treatment on the basis of our study.

The recent standard of care for newly diagnosed patients has been eye drops – more and more – and still more – until they need surgery. If surgery doesn’t work, they go back on eye drops. But now we know there is an alternative. SLT has proved itself to be adept at controlling and preventing the deterioration of glaucoma. Our research is already having a positive and profound impact on patients with newly diagnosed glaucoma outside of the UK – is it time it starts having an impact here, too?

References

  1. G Gazzard et al., “Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial”, Lancet, 393, 1505 (2019). PMID: 30862377.

About the Author(s)

Gus Gazzard

Gus Gazzard is a consultant ophthalmic surgeon and director of surgery at Moorfields Eye Hospital in London; Professor of Ophthalmology, Glaucoma Studies at University College London, and visiting Professor at NYU Langone-Health. He is Past President of the UK & Ireland Glaucoma Society. He was the chief investigator of the LiGHT Trial and in the last 10 years has consulted for Alcon Laboratories. Allergan/Abbvie, Balance Ophthalmics, Bausch & Lomb, Belkin Vision, Ciliatech, Elios Vision, Essential Pharma, Eyetronic, Genentech/Roche, Glaukos, Haag-Streit Group, Iantrek, iStar Medical, Ivantis, Lumenis, McKinsey, Nova EyeMedical, Oertli, Quantel/Ellex Lumibird, Rayner Ltd, Reichert, Ripple Therapeutics, Santen, Sight Sciences, Thea, Topcon, Vialase, Visufarma, and Zeiss. Contact him at g.gazzard@nhs.net

More Articles by Gus Gazzard

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: